Works matching IS 17597706 AND DT 2023 AND VI 14 AND IP 32

Results: 9

Pulmonary pleomorphic carcinoma treated with PD‐1 inhibitor: Two case reports.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3240, doi. 10.1111/1759-7714.15120

By:

Jiang, Tao;
Wang, Hao;
Xue, Fei;
Wu, Xuanpeng;
Ni, Ming;
Wang, Yuanyuan;
Chen, Nanzheng;
Zhang, Yong;
Zhang, Guangjian;
Fu, Junke;
Liu, Xi;
Wu, Qifei

Publication type:

Article

Altered functional connectivity of the nucleus tractus solitarii in patients with chronic cough after lung surgery: an rs‐fMRI study.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3202, doi. 10.1111/1759-7714.15110

By:

Wu, Ming‐sheng;
Chen, Zheng‐wei;
Chen, Xiao;
Wang, Gao‐xiang;
Xu, Chun‐sheng;
Zhu, Yong‐fu;
Xie, Ming‐ran

Publication type:

Article

Radiofrequency ablation for stage <IIB non‐small cell lung cancer: Opportunities, challenges, and the road ahead.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3181, doi. 10.1111/1759-7714.15114

By:

Zhao, Qing;
Wang, Jing;
Fu, Yi‐li;
Hu, Bin

Publication type:

Article

Bronchoscopy for management and identification of etiology of right middle lobe syndrome: Analysis of 66 cases.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3226, doi. 10.1111/1759-7714.15113

By:

Freidkin, Lev;
Heching, Moshe;
Rosengarten, Dror;
Pertzov, Barak;
Gershman, Evgeni;
Izhakian, Shimon;
Amor, Shai M.;
Kramer, Mordechai Reuven

Publication type:

Article

Survival outcomes of east Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR tyrosine kinase inhibitors: A network meta‐analysis of real‐world evidence.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3217, doi. 10.1111/1759-7714.15112

By:

Chang, Huang‐Chih;
Huang, Kuo‐Tung;
Tseng, Chia‐Cheng;
Chen, Yu‐Mu;
Lai, Chien‐Hao;
Chang, Yu‐Ping;
Chen, Yung‐Che;
Chuang, Hung‐Yi;
Wang, Chin‐Chou

Publication type:

Article

Do patient characteristics affect EGFR tyrosine kinase inhibitor treatment outcomes? A network meta‐analysis of real‐world survival outcomes of East Asian patients with advanced non‐small cell lung cancer treated with first‐line EGFR‐TKIs

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3208, doi. 10.1111/1759-7714.15111

By:

Chang, Huang‐Chih;
Wang, Chin‐Chou;
Tseng, Chia‐Cheng;
Huang, Kuo‐Tung;
Chen, Yu‐Mu;
Chang, Yu‐Ping;
Lai, Chien‐Hao;
Fang, Wen‐Feng;
Lin, Meng‐Chih;
Chuang, Hung‐Yi

Publication type:

Article

A multicenter, open‐label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non‐small cell lung cancer.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3232, doi. 10.1111/1759-7714.15115

By:

Yabuki, Yohei;
Hanibuchi, Masaki;
Takeuchi, Eiji;
Haku, Takashi;
Kanematsu, Takanori;
Nishimura, Naoki;
Toyoda, Yuko;
Mitsuhashi, Atsushi;
Otsuka, Kenji;
Sato, Seidai;
Goto, Hisatsugu;
Yoneda, Hiroto;
Ogino, Hirokazu;
Nokihara, Hiroshi;
Tsutomu, Shinohara;
Nishioka, Yasuhiko

Publication type:

Article

Clinical significance of DNA damage response mutations in stage I and stage IIIa NSCLC.

Published in:

Thoracic Cancer, 2023, v. 14, n. 32, p. 3191, doi. 10.1111/1759-7714.15109

By:

Zhang, Haoran;
Zhang, Dongming;
Liu, Jia;
Shi, Yuequan;
Liu, Xiaoyan;
Chen, Minjiang;
Zhong, Wei;
Zhao, Jing;
Xu, Yan;
Wang, Mengzhao

Publication type:

Article

Issue Information.

Published in:: Thoracic Cancer, 2023, v. 14, n. 32, p. 3179, doi. 10.1111/1759-7714.14518
Publication type:: Article